Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8401 to 8415 of 8989 results

  1. Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]

    In development Reference number: GID-TA11455 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene for babies 6 months and over to children under 2 years TS ID 11774

    Discontinued Reference number: GID-TA11124

    Technology appraisal guidance
    Discontinued

  3. Lasmiditan for treating acute migraine [ID3759]

    Discontinued Reference number: GID-TA10807

    Technology appraisal guidance
    Discontinued

  4. Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

    Discontinued Reference number: GID-TA10739

    Technology appraisal guidance
    Discontinued

  5. Sipavibart for preventing COVID-19 [ID6282]

    In development Reference number: GID-TA11352 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Endometriosis: diagnosis and management - surgical management - pain management post-surgery

    Discontinued Reference number: GID-NG10385

    NICE guideline
    Discontinued

  7. Intrapartum care for healthy women and babies - rectal examination after delivery

    Discontinued Reference number: GID-NG10395

    NICE guideline
    Discontinued

  8. Violence and aggression: short-term management in mental health, health and community settings

    Discontinued Reference number: GID-NG10397

    NICE guideline
    Discontinued

  9. Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

    Discontinued Reference number: GID-TAG456

    Technology appraisal guidance
    Discontinued

  10. Clostridium difficile associated diarrhoea - tolevamer [ID378]

    Discontinued Reference number: GID-TAG389

    Technology appraisal guidance
    Discontinued

  11. Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) [ID622]

    Discontinued Reference number: GID-TAG360

    Technology appraisal guidance
    Discontinued

  12. T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

    Discontinued Reference number: GID-TAG433

    Technology appraisal guidance
    Discontinued

  13. Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]

    Discontinued Reference number: GID-TAG332

    Technology appraisal guidance
    Discontinued

  14. Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]

    Discontinued Reference number: GID-TAG435

    Technology appraisal guidance
    Discontinued

  15. Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]

    Discontinued Reference number: GID-TAG425

    Technology appraisal guidance
    Discontinued